MDT · NYSE · STOCK
Medtronic (MDT) Stock Analysis
$92.91
52W $73.31 – $106.33
59/100
$119.49B
24.9
0.57
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is MDT Bullish or Bearish?
Bullish.
Innellis AI committee rates Medtronic plc (MDT) Buy with a composite score of 59/100
, based on 5 analysts with 60% agreement.
Last updated August 24, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.97 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.03 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee sees neither a compelling opportunity nor a clear risk at this stage. Conditions remain neutral — patience is warranted.
Bull & Bear Case
Bull Case
- Dividend yield of 3.5% pays you to wait — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 70 is in overbought territory — Technical
- Weekly RSI at 78 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 24, 2026
Overall Committee Score
59/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 43%
of 192 Healthcare peers
Value Analyst
neutral
58
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Dividend yield of 3.5% pays you to wait
Growth Analyst
bullish
62
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 70 is in overbought territory
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score moved marginally from 59.0 to 59.0.
Comparing 2026-08-23 to 2026-08-24 (1 day apart).
Technical Analysis
RSI (14)
70.1
Overbought
MACD Histogram
0.333
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$89.04
Resistance
$96.23
Bollinger %B
0.88
Inside Bands
Price vs Moving Averages
EMA 9
$91.55
Above
EMA 21
$89.03
Above
EMA 50
$85.91
Above
EMA 200
$87.16
Above
Fundamental Analysis
Valuation
49
Growth
64
Profitability
67
Financial Health
98
Cash Flow
70
Valuation
P/E Ratio
24.9×
P/B Ratio
2.42×
PEG Ratio
7.53
Dividend Yield
3.05%
52W High
$106.33
52W Low
$73.31
Quality & Growth
ROE
970.4%
ROA
516.0%
Gross Margin
6501.8%
Operating Margin
1778.4%
Revenue Growth YoY
—
Debt / Equity
0.57
AI Fundamental Assessment
P/E ratio of 24.9 (inexpensive relative to a 15-40x range); Price-to-book of 2.4x; PEG ratio of 7.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 9.7%; Return on assets of 5.2%; Net margin of 13.2%; Gross margin of 65.0%; Current ratio of 2.13 (healthy short-term liquidity); Debt-to-equity of 0.57; Free cash flow per share is positive (4.23); Most recent quarter missed estimates by 0.4%; EPS growth accelerating (+0.0% -> +14.0% QoQ); Analyst estimates rising over recent quarters
Get the Full MDT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →